Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Plus Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

HOUSTON, SEPT. 25, 2025 (GLOBE NEWSWIRE) -- CNSIDE DIAGNOSTICS, LLC, A WHOLLY-OWNED SUBSIDIARY OFPLUS THERAPEUTICS, INC.(NASDAQ:PSTV) (PLUS OR THE COMPANY), ANNOUNCED TODAY THAT IT HAS SIGNED A NATIONAL AGREEMENT WITH UNITEDHEALTHCARE INSURANCE COMPANY (NYSE: UNH), EFFECTIVESEPTEMBER 15, 2025, COVERING OVER 51 MILLION PEOPLE THROUGHOUTTHE UNITED STATES, TO PROVIDE THE CNSIDE CEREBROSPINAL FLUID TUMOR CELL ENUMERATION LABORATORY DEVELOPED TEST (LDT).

PLUS THERAPEUTICS ANNOUNCES NATIONAL COVERAGE AGREEMENT WITH UNITEDHEALTHCARE INSURANCE COMPANY FOR CNSIDE CEREBROSPINAL FLUID ASSAY FOR METASTATIC CNS CANCER

NON-DILUTIVE PAYMENT IS PART OF $17.6 MILLION AWARD GRANTED FOR THE COMPANY'S LEPTOMENINGEAL CANCER TARGETED RADIOTHERAPEUTIC DEVELOPMENT PROGRAM HOUSTON, SEPT. 22, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ:PSTV) (THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, ANNOUNCES THAT THE COMPANY RECEIVED NOTICE OF AN ADDITIONAL ADVANCE PAYMENT FROM THE CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS (CPRIT), THE SECOND-LARGEST PUBLIC CANCER RESEARCH FUNDER GLOBALLY.

PLUS THERAPEUTICS ANNOUNCES ADDITIONAL $1.9 MILLION ADVANCE PAYMENT FROM CPRIT

CERTIFICATION CRITICAL TO BROAD U.S. MARKET RELEASE OF THE CNSIDE CSF ASSAY PLATFORM CNSIDE NOW MEETS KEY FEDERAL AND STATE REGULATORY REQUIREMENTS, INCLUDING THOSE SET BY THE CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) UNDER THE CLINICAL LAB IMPROVEMENT AMENDMENTS (CLIA) HOUSTON, TEXAS, SEPT. 18, 2025 (GLOBE NEWSWIRE) -- CNSIDE DIAGNOSTICS, LLC, A WHOLLY-OWNED SUBSIDIARY OF PLUS THERAPEUTICS, INC.(NASDAQ:PSTV) (PLUS OR THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, ANNOUNCES THAT IT HAS RECEIVED A CERTIFICATE OF ACCREDITATION FROM CMS FOR ITS LAB LOCATED IN HOUSTON, TEXAS.

PLUS THERAPEUTICS ANNOUNCES SUCCESSFUL ACCREDITATION AND CERTIFICATION FORITS CNSIDE DIAGNOSTICS CLINICAL LABORATORY

HOUSTON, SEPT. 02, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ:PSTV) (PLUS OR THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, ANNOUNCES THAT IT WILL PARTICIPATE IN THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE. THE CONFERENCE IS BEING HELD ON SEPTEMBER 8  10, 2025 AT THE LOTTE NEW YORK PALACE HOTEL.

PLUS THERAPEUTICS TO PARTICIPATE IN FIRESIDE CHAT AT THEH.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

HOUSTON, AUG. 26, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ: PSTV) (THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, TODAY ANNOUNCED THAT IT RECEIVED A LETTER (THE LETTER) FROM NASDAQ ON AUGUST 22, 2025, CONFIRMING ITS COMPLIANCE WITH NASDAQ LISTING RULE 5550(B). SPECIFICALLY, THE LETTER CONFIRMS THAT THE COMPANY IS IN COMPLIANCE WITH BOTH (1) THE MARKET VALUE OF LISTING SECURITIES (MVLS) STANDARD UNDER 5550(B)(2), WHICH REQUIRES CERTAIN COMPANIES TO MAINTAIN A MARKET VALUE OF LISTED SECURITIES OF AT LEAST $35 MILLION (THE MVLS STANDARD), AS WELL AS COMPLIANCE WITH (2) THE ALTERNATIVE STOCKHOLDERS' EQUITY THRESHOLD UNDER 5550(B)(1), WHICH REQUIRES CERTAIN COMPANIES TO MAINTAIN STOCKHOLDERS' EQUITY OF AT LEAST $2.5 MILLION (THE EQUITY STANDARD).

PLUS THERAPEUTICS REGAINS COMPLIANCE WITH APPLICABLE NASDAQ LISTING CRITERIA

REYOBIQ PRODUCED A CLINICAL BENEFIT RATE OF OVER 75% IN 3 CLINICALLY RELEVANT OUTCOME MEASURES RNA SEQUENCING AND CIRCULATING TUMOR CELL REDUCTION CONSISTENT WITH TUMOR CELL DEATH NO DOSE LIMITING TOXICITIES WERE OBSERVED WITH AN OVERALL FAVORABLE SAFETY PROFILE HOUSTON, AUG. 18, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ:PSTV) (THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, ANNOUNCES POSITIVE DATA FROM THE RESPECT-LM PHASE 1 SINGLE DOSE ESCALATION TRIAL PRESENTED AT THE PODIUM AT THE SNO/ASCO CNS METASTASES CONFERENCE IN BALTIMORE, MD. THE DATA DEMONSTRATED TREATMENT OF LEPTOMENINGEAL METASTASES (LM) WITH REYOBIQ IS FEASIBLE, HAS A MANAGEABLE SAFETY PROFILE, AND SHOWS A PROMISING EFFICACY SIGNAL.

PLUS THERAPEUTICS PRESENTS POSITIVE RESPECT-LM CLINICAL TRIAL RESULTS OF REYOBIQ IN LEPTOMENINGEAL METASTASES

HOUSTON, AUG. 15, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ:PSTV) (PLUS OR THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, TODAY ANNOUNCED IT REPORTED STOCKHOLDERS' EQUITY OF $3MILLION AND THEREFORE SATISFIED NASDAQ LISTING RULE 5550(B)(1) (THE EQUITY RULE), AS OF JUNE30, 2025. THE EQUITY RULE REQUIRES LISTED COMPANIES TO MAINTAIN A MINIMUM OF $2.5MILLION IN STOCKHOLDERS' EQUITY.

PLUS THERAPEUTICS REPORTS STOCKHOLDERS' EQUITYIN EXCESS OF $2.5 MILLION IN COMPLIANCE WITH NASDAQ EQUITY REQUIREMENTS

ANNOUNCED CNSIDE CSF ASSAY PLATFORM LAUNCH TIMELINE INITIATED THE REYOBIQ DOSE OPTIMIZATION TRIAL FOR PATIENTS WITH LEPTOMENINGEAL METASTASES HOUSTON, AUG. 14, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ: PSTV) (PLUS OR THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, TODAY ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDES AN OVERVIEW OF RECENT AND UPCOMING BUSINESS HIGHLIGHTS. THE SECOND QUARTER OF 2025 MARKED STEADY EXECUTION AND PROGRESS ON OUR KEY STRATEGIC INITIATIVES: CLINICAL DEVELOPMENT OF OUR RADIOTHERAPEUTIC AND THE ADVANCEMENT OF OUR DIAGNOSTIC PLATFORM TECHNOLOGIES TOWARD COMMERCIALIZATION, SAID MARC H.

PLUS THERAPEUTICS REPORTS SECOND QUARTER FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

CNSIDE CAN QUANTIFY LEPTOMENINGEAL METASTASES (LM) OVER TIME AND MONITOR CHANGES IN THE EXPRESSION OF MULTIPLE TARGETABLE MUTATIONS

PLUS THERAPEUTICS PRESENTS POSITIVE CNSIDE CSF ASSAY PLATFORM RESULTS AT THE2025 SNO/ASCO CNS METASTASES CONFERENCE

CNSIDE AVAILABLE FOR THE STATE OF TEXAS IN AUGUST 2025 INITIAL COMMERCIAL FOCUS ON NCI-DESIGNATED CANCER CENTERS AND LARGE PRIVATE HEALTHCARE SYSTEMS COMPANY WILL EXPAND TESTING SERVICES AND BROADEN REGIONAL AVAILABILITY OVER THE NEXT 12 MONTHS HOUSTON, JULY 31, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ:PSTV) (THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, ANNOUNCES THAT ITS WHOLLY-OWNED SUBSIDIARY, CNSIDE DIAGNOSTICS, LLC (CNSIDE) WILL MAKE CNSIDE CEREBROSPINAL FLUID (CSF) ASSAY PLATFORM AND TESTING SERVICES COMMERCIALLY AVAILABLE IN TEXAS IN AUGUST 2025. INITIAL COMMERCIAL FOCUS WILL BE ON NATIONAL CANCER INSTITUTE (NCI) DESIGNATED CANCER CENTERS, WHICH TREAT THE HIGHEST NUMBER OF PATIENTS AT RISK FOR LEPTOMENINGEAL METASTASES (LM) AND PREVIOUSLY USED CNSIDE.

Plus Therapeutics, Inc.

PSTV

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Plus Therapeutics, Inc.

PSTV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PSTV